Neurosteroids, Anxiety and Quality of Life in Acromegaly

Hacioglu B., Burhan S., Arslan H. F., Balci O., Ozderya A., Pişkinpaşa M. E., ...Daha Fazla

Bratislava Medical Journal, cilt.126, sa.8, ss.1916-1922, 2025 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 126 Sayı: 8
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1007/s44411-025-00180-y
  • Dergi Adı: Bratislava Medical Journal
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE
  • Sayfa Sayıları: ss.1916-1922
  • Anahtar Kelimeler: Acromegaly, Anxiety, Neurosteroids, Quality of life
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Objective: Acromegaly reduces quality of life. Neurosteroids can impact neuropsychological status and anxiety, but their effects on anxiety in acromegaly cases and quality of life are unclear. This study aims to evaluate the relationship between neurosteroids, anxiety, and quality of life in acromegaly patients. Design: This study included 33 cases in the acromegaly group (AG) and 30 healthy subjects in the control group (CG). Beck Anxiety Inventory (BAI) and Short Form-36 (SF-36) were used to assess anxiety levels and Quality of Life (QoL), respectively. The research assessed how anxiety and quality of life scores correlate with the concentrations of growth hormone, IGF-1, and specific neurosteroids (Allopregnanolone (AP), pregnenolone (PRG), 24S-hydroxycholesterol (24OHC), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), androsterone (ADT)). Results: AG had significantly higher BAI scores in comparison to CG. The SF-36 subdomain scores of general health, physical functioning, role limitations due to physical health, energy/fatigue, emotional well-being, social functioning, and pain were significantly lower in the AG. Conclusion: Neurosteroids may affect the quality of life and be associated with depression and anxiety levels in acromegaly.